Rezurock (belumosudil) / Romeck Pharma, Sanofi 
Welcome,         Profile    Billing    Logout  
 0 Diseases   12 Trials   12 Trials   593 News 


«123456789»
  • ||||||||||  Orencia (abatacept) / BMS
    [VIRTUAL] A PERSONALIZED ORGAN-BASED APPROACH TO THE TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (On-Demand Library) -  Feb 4, 2021 - Abstract #EBMT2021EBMT_1724;    
    In contrast, Pomalidomide, carfilzomib, and pentostatin were only effective in less than 23 percent in oral GvHD.Musculoskeletal-GvHD responded best to Ruxolitinib and Belomosudil at 100 and 73% respectively...For lung GvHD (BOS), 5/12 treatments reported a RR which was only 11-12% in those treated with Hydroxychloroquine, and Abatacept... Most of the GvHD trials conducted are focused on the overall response rate (ORR), partial, and complete response amongst transplant patients and the evidence for organ-specific response is limited and therefore our study results are striking for RR yields for some of the organs. Thus, a personalized organ-based approach to the selection of therapeutic agents in cGvHD can result in a more favorable patient outcome and achieving a better organ-specific response while minimizing toxicity and side effects.
  • ||||||||||  Orencia (abatacept) / BMS
    [VIRTUAL] A PERSONALIZED ORGAN-BASED APPROACH TO THE TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (On-Demand Library) -  Feb 4, 2021 - Abstract #EBMT2021EBMT_1723;    
    In contrast, Pomalidomide, carfilzomib, and pentostatin were only effective in less than 23 percent in oral GvHD.Musculoskeletal-GvHD responded best to Ruxolitinib and Belomosudil at 100 and 73% respectively...For lung GvHD (BOS), 5/12 treatments reported a RR which was only 11-12% in those treated with Hydroxychloroquine, and Abatacept... Most of the GvHD trials conducted are focused on the overall response rate (ORR), partial, and complete response amongst transplant patients and the evidence for organ-specific response is limited and therefore our study results are striking for RR yields for some of the organs. Thus, a personalized organ-based approach to the selection of therapeutic agents in cGvHD can result in a more favorable patient outcome and achieving a better organ-specific response while minimizing toxicity and side effects.
  • ||||||||||  Orencia (abatacept) / BMS
    [VIRTUAL] A PERSONALIZED ORGAN-BASED APPROACH TO THE TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (On-Demand Library) -  Feb 4, 2021 - Abstract #EBMT2021EBMT_1722;    
    In contrast, Pomalidomide, carfilzomib, and pentostatin were only effective in less than 23 percent in oral GvHD.Musculoskeletal-GvHD responded best to Ruxolitinib and Belomosudil at 100 and 73% respectively...For lung GvHD (BOS), 5/12 treatments reported a RR which was only 11-12% in those treated with Hydroxychloroquine, and Abatacept... Most of the GvHD trials conducted are focused on the overall response rate (ORR), partial, and complete response amongst transplant patients and the evidence for organ-specific response is limited and therefore our study results are striking for RR yields for some of the organs. Thus, a personalized organ-based approach to the selection of therapeutic agents in cGvHD can result in a more favorable patient outcome and achieving a better organ-specific response while minimizing toxicity and side effects.
  • ||||||||||  Orencia (abatacept) / BMS
    [VIRTUAL] A PERSONALIZED ORGAN-BASED APPROACH TO THE TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (On-Demand Library) -  Feb 4, 2021 - Abstract #EBMT2021EBMT_1721;    
    In contrast, Pomalidomide, carfilzomib, and pentostatin were only effective in less than 23 percent in oral GvHD.Musculoskeletal-GvHD responded best to Ruxolitinib and Belomosudil at 100 and 73% respectively...For lung GvHD (BOS), 5/12 treatments reported a RR which was only 11-12% in those treated with Hydroxychloroquine, and Abatacept... Most of the GvHD trials conducted are focused on the overall response rate (ORR), partial, and complete response amongst transplant patients and the evidence for organ-specific response is limited and therefore our study results are striking for RR yields for some of the organs. Thus, a personalized organ-based approach to the selection of therapeutic agents in cGvHD can result in a more favorable patient outcome and achieving a better organ-specific response while minimizing toxicity and side effects.
  • ||||||||||  Sarclisa (isatuximab-irfc) / Sanofi
    Enrollment open, Trial completion date, Trial primary completion date, Combination therapy:  Isatuximab in Combination With Novel Agents in RRMM - Master Protocol (clinicaltrials.gov) -  Jan 7, 2021   
    P1/2,  N=66, Recruiting, 
    Belumosudil was well tolerated, allowing pts to remain on treatment and realize potential benefits of sustained therapy. Not yet recruiting --> Recruiting | Trial completion date: Nov 2024 --> Feb 2025 | Trial primary completion date: Apr 2023 --> Jul 2023
  • ||||||||||  belumosudil (KD025 ) / Kadmon, Romeck Pharma
    Belumosudil? (Twitter) -  Dec 5, 2020   
  • ||||||||||  belumosudil (KD025 ) / Kadmon, Romeck Pharma, KD-025 CAR T-cells / KAEDI
    Clinical, Journal:  KD025, an anti-adipocyte differentiation drug, enhances the efficacy of conventional chemotherapeutic drugs in ABCG2-overexpressing leukemia cells. (Pubmed Central) -  Oct 26, 2020   
    KD025 (SLx-2119) is a novel Rho-associated protein kinase 2-selective inhibitor, which has been shown to inhibit adipogenesis in human adipose-derived stem cells and restore impaired immune homeostasis in autoimmunity therapy...Moreover, KD025 significantly inhibited the efflux of [H]-mitoxantrone and hence accumulated higher levels of [H]-mitoxantrone in HL60/ABCG2 cells...Taken together, KD025 can sensitize conventional antineoplastic drugs in ABCG2-overexpressing leukemia cells by blocking the pump function of ABCG2 protein. The present findings may provide a novel and useful combinational therapeutic strategy of KD025 and antineoplastic drugs for leukemia patients with ABCG2-mediated MDR.
  • ||||||||||  Rezurock (belumosudil) / Romeck Pharma, Sanofi
    Trial completion date, Trial primary completion date:  KD025 Hepatic Impairment Study With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment (clinicaltrials.gov) -  Sep 1, 2020   
    P1,  N=40, Recruiting, 
    The present findings may provide a novel and useful combinational therapeutic strategy of KD025 and antineoplastic drugs for leukemia patients with ABCG2-mediated MDR. Trial completion date: Dec 2020 --> Mar 2021 | Trial primary completion date: Aug 2020 --> Feb 2021
  • ||||||||||  KD025  / Kadmon, Romeck Pharma, KD-025 CAR T-cells / KAEDI
    Journal:  Identification of novel functions of the ROCK2-specific inhibitor KD025 by bioinformatics analysis. (Pubmed Central) -  Apr 9, 2020   
    In addition, we found KD025 has novel regulatory functions on various pathways, including oxidative phosphorylation, WNT signaling, angiogenesis, and KRAS signaling. Further studies are required to systematically characterize these newly identified functions of KD025.
  • ||||||||||  KD025  / Kadmon, Romeck Pharma, KD-025 CAR T-cells / KAEDI
    Journal:  KD025 (SLx-2119) suppresses Adipogenesis at Intermediate Stage in Human Adipose-derived Stem Cells. (Pubmed Central) -  Mar 26, 2020   
    In addition, we observed that other ROCK inhibitors such as Y-27632, fasudil, and H-1152P did not suppress but promoted adipocyte differentiation. These results indicate that KD025 suppresses adipocyte differentiation by modulation of key factors activated at the intermediate stage of differentiation, and not by inhibition of ROCK2.
  • ||||||||||  Rezurock (belumosudil) / Romeck Pharma, Sanofi
    Trial completion date, Trial primary completion date:  A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease (clinicaltrials.gov) -  Mar 16, 2020   
    P2a,  N=88, Active, not recruiting, 
    These results indicate that KD025 suppresses adipocyte differentiation by modulation of key factors activated at the intermediate stage of differentiation, and not by inhibition of ROCK2. Trial completion date: Jan 2020 --> Dec 2020 | Trial primary completion date: Jan 2020 --> Oct 2020